Biogen Idec, San Diego, CA, USA.
MAbs. 2011 Jul-Aug;3(4):338-51. doi: 10.4161/mabs.3.4.16615. Epub 2011 Jul 1.
The use of monoclonal antibodies (mAbs) has become a general approach for specifically targeting and treating human disease. In oncology, the therapeutic utility of mAbs is usually evaluated in the context of treatment with standard of care, as well as other small molecule targeted therapies. Many anti-cancer antibody modalities have achieved validation, including the targeting of growth factor and angiogenesis pathways, the induction of tumor cell killing or apoptosis, and the blocking of immune inhibitory mechanisms to stimulate anti-tumor responses. But, as with other targeted therapies, few antibodies are curative because of biological complexities that underlie tumor formation and redundancies in molecular pathways that enable tumors to adapt and show resistance to treatment. This review discusses the combinations of antibody therapeutics that are emerging to improve efficacy and durability within a specific biological mechanism (e.g., immunomodulation or the inhibition of angiogenesis) and across multiple biological pathways (e.g., inhibition of tumor growth and induction of tumor cell apoptosis).
单克隆抗体（mAbs）的应用已成为针对人类疾病进行特异性靶向治疗的通用方法。在肿瘤学中，mAbs 的治疗效用通常在与标准护理以及其他小分子靶向治疗联合应用的背景下进行评估。许多抗癌抗体治疗方式已得到验证，包括针对生长因子和血管生成途径的靶向治疗、诱导肿瘤细胞杀伤或凋亡以及阻断免疫抑制机制以刺激抗肿瘤反应。但是，与其他靶向治疗一样，由于肿瘤形成的生物学复杂性以及使肿瘤能够适应和对治疗产生耐药性的分子途径中的冗余性，很少有抗体具有治愈作用。本文综述了新兴的抗体治疗组合，以提高特定生物学机制（如免疫调节或血管生成抑制）和多个生物学途径（如抑制肿瘤生长和诱导肿瘤细胞凋亡）内的疗效和持久性。
